subscribeSubscribe
price-trendAsk Us
Ultragenyx, Dojolvi Gets Approval in Brazil for Fatty Acid Oxidation Disorders

Ultragenyx, Dojolvi Gets Approval in Brazil for Fatty Acid Oxidation Disorders
GLOBENEWSWIRE
23 Aug 2021
Share Share
Ultragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin)

Ultragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin)
PRESS RELEASE
17 Feb 2021
Share Share
Ultragenyx Announces U.S. Commercial Launch of Dojolvi™ (triheptanoin)

Ultragenyx Announces U.S. Commercial Launch of Dojolvi™ (triheptanoin)
GLOBENEWSWIRE
22 Jul 2020
Share Share
Orsini Services Expands Partnership With Ultragenyx To Provide Dojolvi™

Orsini Services Expands Partnership With Ultragenyx To Provide Dojolvi™
PRNEWSWIRE
10 Jul 2020
Share Share
FDA backs second rare disease drug from Ultragenyx in the space of a fortnight

FDA backs second rare disease drug from Ultragenyx in the space of a fortnight
Richard Staines PHARMAPHORUM
04 Jul 2020
Share Share
PANTHERx® Rare Pharmacy Selected by Ultragenyx Pharma to Distribute DOJOLVI™

PANTHERx® Rare Pharmacy Selected by Ultragenyx Pharma to Distribute DOJOLVI™
PRNEWSWIRE
03 Jul 2020
Share Share
FDA Approvals Roundup: Fintepla, Dojolvi, Phesgo

FDA Approvals Roundup: Fintepla, Dojolvi, Phesgo
R. Matthews RAPS
02 Jul 2020
Share Share
Ultragenyx Announces U.S. FDA Approval of Dojolvi™ (UX007/triheptanoin)

Ultragenyx Announces U.S. FDA Approval of Dojolvi™ (UX007/triheptanoin)
PRESS RELEASE
30 Jun 2020
Share Share
FDA accepts Ultragenyx`s triheptanoin NDA for rare oxidation disorders

FDA accepts Ultragenyx`s triheptanoin NDA for rare oxidation disorders
Douglas W. House SEEKINGAPLPHA
14 Oct 2019
Share Share
This Biotech Is Flirting With A Breakout After FDA Decision On Drug

This Biotech Is Flirting With A Breakout After FDA Decision On Drug
Allison Gatlin INVESTORS
29 Aug 2018
Share Share